Octreo-SPECT/CT imaging for accurate detection and localization of suspected neuroendocrine tumors

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 52, Issue 4, 2008, Pages 323-333

  Perri, Marzio ^a   Erba, P ^a   Volterrani, D ^a   Lazzeri, E ^a   Boni, G ^a   Grosso, M ^a   Mariani, G ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

111In octreotide, DTPA(0); Neuroendocrine tumors; Radionuclide imaging; Receptors, somatostatin; Tomography, emission computer; Tomography, emission computed, single photon

Indexed keywords

PENTETREOTIDE; PENTETREOTIDE IN 111; TUMOR MARKER;

ABDOMINAL RADIOGRAPHY; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL TRIAL; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FALSE POSITIVE RESULT; FEMALE; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY COMPUTER ASSISTED TOMOGRAPHY; THORAX RADIOGRAPHY; TUMOR CLASSIFICATION; TUMOR LOCALIZATION; TUMOR SCINTISCANNING;

ABDOMEN; ADULT; AGED; AGED, 80 AND OVER; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; PARAGANGLIOMA; PENTETIC ACID; RADIOGRAPHY, ABDOMINAL; RADIOGRAPHY, THORACIC; RECURRENCE; ROC CURVE; SENSITIVITY AND SPECIFICITY; THORAX; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 60549097441     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Buchanan KD, Johnston CF, O'Hare MM, Ardill JE, Shaw C, Collins JS et al. Neuroendocrine tumors. A European view. Am J Med 1986;81:14-22.
2. Solcia E, Kloppel G, Sobin LH. Histological typing of endocrine turnours. 2nd ed. Heidelberg: World Health Organization; 2000.
3. 3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716-31.
4. Balon HR, Goldsmith SJ, Siegel BA, Silberstein EB, Krenning EP, Lang O et al. Procedure guideline for somatostatin receptor scintigraphy with 111In-Pentetreotide. J Nucl Med 2001;42:1134-1138.
5. 111In-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 2003;5:42-8.
6. 111In-DTPA-octreotide. J Nucl Med 2006;47:566-73.
7. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004;25:458-511.
8. Ramage JK, Davies AH, Ardill J, Bax N, Caplin M, Fgrossman A et al. UKNETwork for Neuroendocrine Tumours. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 2005;54:1-16.
9. Ricke J, Klose KJ, Mignon M, Oberg K, Wiedenmann B. Standardisation of imaging in neuroendocrine tumours: results of a European delphi process. Eur J Radiol 2001;37:8-17.
10. Slooter GD, Mearadji A, Breeman VA, Marquet RL, de Jong M, Krenning EP et al. Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours. Br J Surg. 2001;88:31-40.
11. Gibril F, Reynolds JC, Doppman JL, Chen CC, Venzon DJ, Termanini B et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 1996;125:26-34.
12. Gibril F, Reynolds JC, Chen CC, Yu F, Goebel SU, Serrano J et al. Specificity of somatostatin receptor scintigraphy: a prospective Study and effects of false-positive localizations on management in patients with gastrinomas. J Nucl Med 1999;40:539-53.
13. Even-Sapir E, Keidar Z, Sachs J, Engel A, Bettman L, Gaitini D et al. The new technology of combined transmission and emission tomography in evaluation of endocrine neoplasms. J Nucl Med 2001; 42:998-1004.
14. 111In-octreotide scintigraphy and low-dose computed tomography in localization of neuroendocrine tumors. Clin Nucl Med 2003;28:506-8.
15. Pfannenberg AC, Eschmann SM, Horger M, Lamberts R, Vonthein R, Claussen CD et al. Benefit of anatomical-functional image fusion in the diagnostic work-up of neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging 2003;30:835-43.
16. Ingui CJ, Shah NP, Oates ME. Endocrine neoplasm scintigraphy: added value of fusing SPECT/CT images compared with traditional side-by-side analysis. Clin Nucl Med 2006;31:665-72.
17. Schillaci O. Hybrid SPECT/CT: a new era for SPECT imaging? Eur J Nucl Med Mol Imaging 2005;32:521-4.
18. 111In-Pentetreotide in assessment of neuroendocrine tumours. Clin Endocrinol 2003;59:565-73.
19. Hillel PG, van Beek EJ, Taylor C, Lorenz E, Bax ND, Prakash V et al. The clinical impact of a combined gamma camera/CT imaging system on somatostatin receptor imaging of neuroendocrine tumours. Clin Radiol 2006;61:579-87.
20. Amthauer H, Denecke T, Rohlfing T, Ruf J, Böhmig M, Gutberlet M et al. Value of image fusion using single photon emission computed tomography with integrated low dose computed tomography in comparison with a retrospective voxel-based method in neuroendocrine tumours. Eur Radiol 2005;15:1456-62.
21. Metz CE. ROC methodology in radiologic imaging. Invest Radiol 1986;21:720-33.
22. Obuchowski NA. Receiver operating characteristic curves and their use in radiology. Radiology 2003;229:3-8.
23. Dromain C, de Baere T, Baudin E, Galline J, Ducreux M, Boige V et al. MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques. Am J Roentgenol 2003;180:121-8.
24. Panzuto F, Falconi M, Nasoni S, Angeletti S, Moretti A, Bezzi M et al. Staging of digestive endocrine tumours using helical computed tomography and somatostatin receptor scintigraphy. Ann Oncol 2003;14:586-91.
25. Kumbasar B, Kamel IR, Tekes A, Eng J, Fishman EK, Wahl RL. Imaging of neuroendocrine tumors: accuracy of helical CT versus SRS. Abdom Imaging 2004;29:696-702.
26. Dromain C, de Baere T, Lumbroso J, Caillet H, Laplanche A, Boige V et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol 2005;23:70-80.
27. Horton KM, Hruban RH, Yeo C, Fishman EK. Multi-detector row CT of pancreatic islet cell tumors. Radiographics 2006;26:453-64.
28. Adams S, Baum R, Rink T, Schumm-Drager PM, Usadel KH, Hor G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumors. Eur J Nucl Med 1998;25:7983.
29. Pasquali C, Rubello D, Sperti C, Gasparoni P, Liessi G, Chierichetti F et al. Neuroendocrine tumor imaging: can F-18 fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior? World J Surg 1998;22:588-92.
30. 111In-Pentetreotide in the PET era. QJ Nucl Med Mol Imaging 2005;49:225-35.
31. 18F-FDOPA PET. J Nucl Med 2004;45: 1161-7.
32. Sundin A, Eriksson B, Bergstrom M, Langstrom B, Oberg K, Orlefors H. PET in the diagnosis of neuroendocrine tumors. Ann N Y Acad Sci 2004;1014:246-57.
33. 11C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 2005;90:3392-400.
34. Win Z, Al-Nahhas A, Rubello D, Gross MD. Somatostatin receptor PET imaging with Gallium-68 labeled peptices. Q J Nucl Med Mol Imaging 2007;51:244-50.
35. 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007;34:1617-26.
36. Bocher M, Balan A, Krausz Y, Shrem Y, Lonn A, Wilk W et al. Gamma camera-mounted anatomical X-ray tomography: technology, system characteristics and first images. Eur J Nucl Med 2000;27:619-27.
37. Bertherat J, Tenenbaum F, Perlemoine K, et al. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. J Clin Endocrinol Metab 2003;88:5353-60.
38. Cescato R, Schulz S, Waser B, Eltschinger V, Rivier JE, Wester HJ et al. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. J Nucl Med 2006;47:502-11.